Compare NBHC & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | RLAY |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2011 | 2020 |
| Metric | NBHC | RLAY |
|---|---|---|
| Price | $38.72 | $10.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $45.33 | $14.50 |
| AVG Volume (30 Days) | 499.1K | ★ 2.3M |
| Earning Date | 04-28-2026 | 05-27-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ 2.85 | N/A |
| Revenue | ★ $47,100,000.00 | $15,355,000.00 |
| Revenue This Year | $39.32 | N/A |
| Revenue Next Year | $6.74 | $396.00 |
| P/E Ratio | $13.65 | ★ N/A |
| Revenue Growth | 2.86 | ★ 53.44 |
| 52 Week Low | $32.83 | $1.78 |
| 52 Week High | $42.99 | $11.43 |
| Indicator | NBHC | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 36.76 | 60.91 |
| Support Level | $37.79 | $9.06 |
| Resistance Level | $40.97 | $11.43 |
| Average True Range (ATR) | 0.97 | 0.77 |
| MACD | -0.25 | 0.06 |
| Stochastic Oscillator | 11.50 | 56.56 |
National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit cards, wire transfers, automated clearing house, and electronic bill payments.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).